Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of JPY 3.14 trillion. The enterprise value is 3.83 trillion.

Market Cap	3.14T
Enterprise Value	3.83T

Important Dates

The next estimated earnings date is Tuesday, October 29, 2024.

Earnings Date	Oct 29, 2024
Ex-Dividend Date	Sep 27, 2024

Share Statistics

Astellas Pharma has 1.79 billion shares outstanding. The number of shares has decreased by -1.06% in one year.

Shares Outstanding	1.79B
Shares Change (YoY)	-1.06%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	54.45%
Float	1.73B

Valuation Ratios

The trailing PE ratio is 146.35 and the forward PE ratio is 84.45. Astellas Pharma's PEG ratio is 1.09.

PE Ratio	146.35
Forward PE	84.45
PS Ratio	1.84
PB Ratio	1.87
P/FCF Ratio	23.98
PEG Ratio	1.09

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.77, with an EV/FCF ratio of 29.25.

EV / Earnings	177.92
EV / Sales	2.25
EV / EBITDA	13.77
EV / EBIT	41.08
EV / FCF	29.25

Financial Position

The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.59.

Current Ratio	0.90
Quick Ratio	0.66
Debt / Equity	0.59
Debt / EBITDA	3.55
Debt / FCF	7.58
Interest Coverage	6.90

Financial Efficiency

Return on equity (ROE) is 1.32% and return on invested capital (ROIC) is 2.58%.

Return on Equity (ROE)	1.32%
Return on Assets (ROA)	1.82%
Return on Capital (ROIC)	2.58%
Revenue Per Employee	115.35M
Profits Per Employee	1.46M
Employee Count	14,754
Asset Turnover	0.52
Inventory Turnover	1.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-15.03%
50-Day Moving Average	1,736.75
200-Day Moving Average	1,646.47
Relative Strength Index (RSI)	52.31
Average Volume (20 Days)	6,102,160

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of JPY 1.70 trillion and earned 21.52 billion in profits. Earnings per share was 11.96.

Revenue	1.70T
Gross Profit	1.39T
Operating Income	95.13B
Pretax Income	28.61B
Net Income	21.52B
EBITDA	279.99B
EBIT	95.13B
Earnings Per Share (EPS)	11.96

Full Income Statement

Balance Sheet

The company has 302.93 billion in cash and 992.66 billion in debt, giving a net cash position of -689.73 billion or -384.65 per share.

Cash & Cash Equivalents	302.93B
Total Debt	992.66B
Net Cash	-689.73B
Net Cash Per Share	-384.65
Equity (Book Value)	1.68T
Book Value Per Share	936.24
Working Capital	-133.15B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 172.88 billion and capital expenditures -41.99 billion, giving a free cash flow of 130.89 billion.

Operating Cash Flow	172.88B
Capital Expenditures	-41.99B
Free Cash Flow	130.89B
FCF Per Share	72.99

Full Cash Flow Statement

Margins

Gross margin is 81.51%, with operating and profit margins of 5.59% and 1.26%.

Gross Margin	81.51%
Operating Margin	5.59%
Pretax Margin	1.68%
Profit Margin	1.26%
EBITDA Margin	16.45%
EBIT Margin	5.59%
FCF Margin	7.69%

Dividends & Yields

This stock pays an annual dividend of 74.00, which amounts to a dividend yield of 4.19%.

Dividend Per Share	74.00
Dividend Yield	4.19%
Dividend Growth (YoY)	10.77%
Years of Dividend Growth	8
Payout Ratio	583.25%
Buyback Yield	1.06%
Shareholder Yield	5.25%
Earnings Yield	0.68%
FCF Yield	4.17%

Dividend Details

Stock Splits

The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2014
Split Type	Forward
Split Ratio	5

Scores

Astellas Pharma has an Altman Z-Score of 1.73. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.73
Piotroski F-Score	n/a